Randomised controlled trial of the impact of haemodiafiltration on uraemic neuropathy: FINESSE study protocol.

ABSTRACT:

Introduction

The majority of patients undergoing haemodialysis (HD) show evidence of uraemic neuropathy, a condition with no known disease-modifying treatments. The pathogenesis of uraemic neuropathy is poorly understood, but may be related to cumulative exposure to middle molecules or other solutes such as potassium. It is not known whether haemodiafiltration (HDF) reduces the progression of uraemic neuropathy.

Methods and analysis

Filtration In the Neuropathy of End-Stage kidney disease Symptom Evolution (FINESSE) is a multicentre, randomised, open-label, blinded endpoint assessment, controlled trial designed to assess the impact of HDF versus HD on uraemic neuropathy. Maintenance HD patients will be randomised in a 1:1 ratio to receive HDF or HD with high-flux membranes f

SUBMITTER: Smyth B 

PROVIDER: S-EPMC6340424 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature